We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MSB market cap is 1.08B. The company's latest EPS is USD -0.1194 and P/E is -12.06.
Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 33.07M | 26.19M | 17.02M | 19.85M | 9.25M |
Operating Income | -74.81M | -90.41M | -73.76M | -60.44M | -65.14M |
Net Income | -77.94M | -98.81M | -91.35M | -81.89M | -87.96M |
Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 733.6M | 744.72M | 662.14M | 669.42M | 669.15M |
Total Liabilities | 184.28M | 163.32M | 165.1M | 167.58M | 188.8M |
Total Equity | 549.33M | 581.4M | 497.04M | 501.84M | 480.36M |
Year End 30 June 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -56.37M | -106.68M | -65.78M | -63.27M | -48.46M |
Investing | -3.27M | -1.65M | -232k | -194k | -97k |
Financing | 137.04M | 114.47M | -9.87M | 74.5M | 40.25M |
Market Cap | 1.08B |
Price to Earnings Ratio | -12.06 |
Price to Sales Ratio | 114.29 |
Price to Cash Ratio | 16.84 |
Price to Book Ratio | 2.21 |
Dividend Yield | - |
Shares Outstanding | 736.58M |
Average Volume (1 week) | 7.57M |
Average Volume (1 Month) | 4.07M |
52 Week Change | 301.37% |
52 Week High | 1.83 |
52 Week Low | 0.255 |
Spread (Intraday) | 0.01 (0.34%) |
Company Name | Mesoblast Limited |
Address |
level 38 melbourne, victoria 3000 |
Website | https://www.mesoblast.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions